Our News & Updates

Diagnostics, Press Releases

XPhyto signs Distribution Agreement for Czech Republic, rollout planned for Hungary, Slovakia, Ukraine and Russia

Jan 13, 2022

Vancouver, Canada, and Uttenweiler, Germany (January 13, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to announce...

Continue Reading

Press Releases

XPhyto Announces New Director of Business Development and Head of Diagnostic Research

Jan 10, 2022

Vancouver, Canada, and Uttenweiler, Germany (January 10, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to announce...

Continue Reading

Drug Delivery, Press Releases

XPhyto Epilepsy clinical trial planned in 2022 with its proprietary fast-dissolving CBD oral strips

Dec 15, 2021

Vancouver, Canada, and Uttenweiler, Germany (December 15, 2021) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to provide...

Continue Reading

Press Releases

XPhyto Completes Strategic Acquisition of 3a-diagnostics GmbH

Dec 6, 2021

The acquisition positions XPhyto to be a leading Biosensor producer integrating thin film technology with 3a-diagnostics biosensor technologyThe acquisition of 3a, a German-based rapid point-of-care...

Continue Reading

Press Releases

XPhyto Therapeutics Closes Private Placements for Gross Proceeds of $7,000,0000

Nov 29, 2021

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC – November 26, 2021 ‐ XPhyto Therapeutics Corp. (“XPhyto”...

Continue Reading

Press Releases

XPhyto Announces Managing Director Appointment, Financing and 3a-diagnostics Development

Nov 3, 2021

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, Canada, and Uttenweiler, Germany (November 3, 2021) -...

Continue Reading

Drug Delivery, Press Releases

XPhyto Reports Development Update for its Drug Delivery Business

Oct 12, 2021

Rotigotine transdermal skin patch optimization and pivotal study planning underwayRotigotine patch manufacturing, sales and marketing in preparationCannabinoid oral dissolvable film (ODF) programs advanced, CBD ODF...

Continue Reading

Diagnostics, Press Releases

XPhyto Reports Successful Market Launch and Growing Demand for its 25-minute COVID-19 PCR Test COVID-ID Lab

Sep 8, 2021

Vancouver, Canada, and Frankfurt, Germany (September 08, 2021) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to announce...

Continue Reading

Press Releases

XPhyto Launches First Commercial Biosensor for Oral Disease

Aug 30, 2021

Biosensor test dissolves on the tongue and turns bitter indicating the presence of oral inflammation after five minutesEasy and simple at-home self-checks improve oral health...

Continue Reading

Diagnostics, Press Releases

XPhyto’s acquisition target, 3a-diagnostics, reports breakthrough identification of COVID-19 biosensor candidates

Jul 28, 2021

First saliva activated biosensor molecules identified to diagnose COVID-19 infection using XPhyto’s oral dissolvable delivery platformBiosensor candidates are ready for optimization and performance assessmentDevelopment of...

Continue Reading

Diagnostics, Press Releases

XPhyto signs transformative acquisition agreement with 3a-diagnostics, to enter hi-tech biosensor market and expand its diagnostic product portfolio

Jul 20, 2021

The acquisition creates significant commercial development and manufacturing opportunities for XPhyto as well as cost synergies and improved margins on its diagnostic products.The acquisition secures...

Continue Reading

Diagnostics, Press Releases

XPhyto Supplies 10 Test Centers in Berlin with 25-minute COVID-19 PCR Test

Jun 30, 2021

XPhyto signs master supply agreement with operator of 10 COVID-19 test centersThe test will be offered to customers as a rapid PCR test with sample...

Continue Reading